Skip to main content
Skip to footer
Opens in a new tab
About
Our Philosophy
Meet Our Care Team
Your Care Experience
Services
Cancer Care
Laboratory Services
Same-Day CT Imaging
Liberty Pharmacy
Infusion Services
Clinical Trials
Is a Clinical Trial Right for Me?
Find a Clinical Trial
Frequently Asked Questions
About PhaseWell Research
Resources
Patient Resources
Patient Forms
Billing & Insurance
Educational Resources
Approved Oncology Drugs (PDF)
Referring Physicians
Contact Us
About
Our Philosophy
Meet Our Care Team
Your Care Experience
Services
Cancer Care
Laboratory Services
Same-Day CT Imaging
Liberty Pharmacy
Infusion Services
Clinical Trials
Is a Clinical Trial Right for Me?
Find a Clinical Trial
Frequently Asked Questions
About PhaseWell Research
Resources
Patient Resources
Patient Forms
Billing & Insurance
Educational Resources
Approved Oncology Drugs (PDF)
Referring Physicians
Contact Us
Category:
Lung
A Phase 3, randomised, double-blind, placebo-controlled, multicentre trial comparing trilaciclib versus placebo in limited-stage small cell lung cancer
September 11, 2026
A Phase 3, Randomized, Open-label Trial of Trastuzumab Deruxtecan with Pembrolizumab vs Platinum-based Chemotherapy with Pembrolizumab as First-line Therapy in HER2-overexpressing, PD-L1 TPS <50% Non-squamous NSCLC (DESTINY-Lung06)
September 11, 2026
A Multicenter, Randomized, Open-label, Phase 2 Study of BMS-986504 Monotherapy in Advanced or Metastatic NSCLC with Homozygous MTAP Deletion After Progression on Prior Therapies
September 11, 2026
An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin with Pembrolizumab vs Pembrolizumab Monotherapy as First-Line Treatment in PD-L1 High Advanced NSCLC (BE6A LUNG-02)
September 11, 2026
A Phase 2/3, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer
September 11, 2026
A Phase 1 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Small Cell Lung Cancer
September 11, 2026
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician’s Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCLC (VIRO-25)
September 11, 2026
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
September 11, 2026
An Open-Label, Phase 2b Global Multicenter Cohort Trial of Zipalertinib in Locally Advanced or Metastatic NSCLC with Exon 20 Insertion and Uncommon/Single or Compound EGFR Mutations
September 11, 2026
A Phase 1/2 Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (ES-SCLC)
September 11, 2026
1
2
→
